US 12,295,920 B2
Composition for treatment, prevention, or amelioration of Alzheimer's disease, a composition for suppression of brain nerve cell death, a composition for suppression of microglia activation induced by amyloid β peptide, and a composition for suppression of PGE2, TNF-α, or IL-1β production induced by amyloid βpeptide
Arisa Fuwa, Itami (JP); Ryusei Uchio, Itami (JP); Kengo Kawasaki, Itami (JP); Koutarou Muroyama, Itami (JP); and Shinji Murosaki, Itami (JP)
Assigned to HOUSE WELLNESS FOODS CORPORATION, Hyogo (JP)
Appl. No. 17/253,906
Filed by House Wellness Foods Corporation, Hyogo (JP)
PCT Filed Jun. 25, 2019, PCT No. PCT/JP2019/025049
§ 371(c)(1), (2) Date Dec. 18, 2020,
PCT Pub. No. WO2020/004357, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 2018-124502 (JP), filed on Jun. 29, 2018.
Prior Publication US 2021/0267914 A1, Sep. 2, 2021
Int. Cl. A61K 31/12 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/12 (2013.01) [A61P 25/28 (2018.01)] 19 Claims
 
1. A method for suppression of microglia activation induced by amyloid β peptide in vivo or in vitro comprising:
administering turmeronol A and turmeronol B to microglia in vivo or in vitro; and
suppressing microglia activation induced by amyloid β peptide,
wherein turmeronol A is administered in an amount of 80 μg or more per day and turmeronol B is administered in an amount of 20 μg or more per day.